Studies of up-regulation of androgen receptors in genital skin fibroblasts.
Prolonged exposure of genital skin fibroblasts (GSF) to dihydrotestosterone (DHT) increases androgen receptor binding of steroid, a process termed 'up-regulation'. Because the extent of up-regulation appears to be quite variable, we have investigated the optimal conditions and the molecular mechanisms that control this phenomenon in seven strains of normal neonatal GSF. When GSF were incubated for 1-48 h with 3 nM methyltrienolone (R1881), maximal up-regulation was reached by 20 h and remained constant thereafter. With DHT, rapid steroid metabolism required replenishment of DHT for maximum up-regulation. Up-regulation levels following 20 h incubation with DHT (including steroid replenishment) and R1881 were 2.07-fold (range = 1.1-3.3) and 2.35-fold (range = 1.86-3.33), respectively. The greater variability observed with DHT may be related to variable rates of steroid catabolism among cell strains. Half-maximal up-regulation was attained at 0.29 nM R1881, which approximates the Kd. Maximal up-regulation was reached only with continuous exposure to R1881 for 24 h. It was completely inhibited by actinomycin D (0.5 micrograms/ml) or cycloheximide (10 micrograms/ml). Following up-regulation, removal of R1881 for 24 h resulted in a highly variable decline of androgen receptors among cell strains. Maximal up-regulation could be reinduced by exposure to R1881 again for an additional 24 h. During up-regulation, androgen receptor levels in nuclei and nuclear matrix rose with increments comparable to those obtained in whole cells. We conclude that the extent of up-regulation and its rate of decline differ greatly among normal cell strains. Hence, its study in cells of patients with androgen insensitivity may have limited value.(ABSTRACT TRUNCATED AT 250 WORDS)
Gad
Y Z
YZ
Division of Pediatric Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Berkovitz
G D
GD
Migeon
C J
CJ
Brown
T R
TR
D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D013196:Dihydrotestosterone / Q000378:metabolism / Q000494:pharmacology; D004963:Estrenes / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects / Q000648:ultrastructure*; D005837:Genitalia, Male / Q000166:cytology; D006801:Humans; D008297:Male; D015741:Metribolone; D011944:Receptors, Androgen / Q000032:analysis / Q000378:metabolism* / Q000493:pharmacokinetics; D012867:Skin / Q000166:cytology
D004963:Estrenes; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D003609:Dactinomycin; D015741:Metribolone; D003513:Cycloheximide